Browse by author
Lookup NU author(s): Professor Ian HicksonORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2021 American Association for Cancer Research.Numerous mechanisms of resistance arise in response to treatment with second-generation androgen receptor (AR) pathway inhibitors in metastatic castration-resistant prostate cancer (mCRPC). Among these, point mutations in the ligand binding domain can transform antagonists into agonists, driving the disease through activation of AR signaling. To address this unmet need, we report the discovery of JNJ-63576253, a next-generation AR pathway inhibitor that potently abrogates AR signaling in models of human prostate adenocarcinoma. JNJ-63576253 is advancing as a clinical candidate with potential effectiveness in the subset of patients who do not respond to or are progressing while on second-generation AR-targeted therapeutics.
Author(s): Branch JR, Bush TL, Pande V, Connolly PJ, Zhang Z, Hickson I, Ondrus J, Jaensch S, Bischoff JR, Habineza G, van Hecke G, Meerpoel L, Packman K, Parrett CJ, Chong YT, Gottardis MM, Bignan G
Publication type: Article
Publication status: Published
Journal: Molecular Cancer Therapeutics
Online publication date: 01/03/2021
Acceptance date: 25/02/2021
ISSN (print): 1535-7163
ISSN (electronic): 1538-8514
Publisher: American Association for Cancer Research Inc.
PubMed id: 33649102
Altmetrics provided by Altmetric